This Viewpoint argues that publication by the European Medicines Agency of clinical study reports as part of its approval process for commercial drugs sets a standard of transparency that could challenge the reputation of the US Food and Drug Administration as the international standard-bearer in drug and device approval.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lnfTAN
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Caring for Patients with Physical Disabilities: Assessment of an Innovative Spinal Cord Injury Session that Addresses an Educational Gap Des...
-
http://orl-agios.blogspot.com/2017/06/the-preclinical-anticancer-effect-of.html Flavonoids present in foods were considered non-absorbable b...
-
World Community; and Remarks on our Own Behalf Models of Anticipation Within the Responsible Research and Innovation Framework: the Two RRI ...
-
Vol.31 No.5 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1k8FKtW via IFTTT
-
Radioterapia oncologica, la Cattolica protagonista al Congresso Europeo insalutenews ... l'utilizzo della radioterapia stereotass...
-
Publication date: Available online 24 December 2017 Source: European Journal of Radiology Author(s): Wenbin Jiang, Hongwei Xue, Qinqin W...
-
Related Articles Promoting the Inclusion of Lung Volumes in the Reversibility Evaluation-Reply. Respir Care. 2017 Feb;62(2):256 Auth...
-
We report an unusual case of a strangulated internal hernia resulting from a right paraduodenal fossa hernia (PDH) in the context of bowel m...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου